Respiratory Syncytial Virus (RSV) Follow-Up Study (MK-0476-374)
Status
Completed
Conditions
Respiratory Syncytial Virus Bronchiolitis
Study type
Observational
Funder types
Industry
Identifiers
Details and patient eligibility
About
This is a prospective, multicenter, observational study in participants who completed the 24-week, placebo-controlled MK-0476 Protocol 272 (NCT00076973) study of montelukast in the treatment of respiratory symptoms subsequent to RSV-induced bronchiolitis. The purpose of this study is to better understand the clinical and demographic correlates of asthma and atopic disorders in children (through the age of 6 years) with a history of severe RSV-induced bronchiolitis.
Enrollment
343 patients
Sex
All
Ages
18 months to 6 years old
Volunteers
No Healthy Volunteers
Inclusion criteria
- successfully completed MK-0476 Protocol 272
- had RSV-induced bronchiolitis at entry into Protocol 272
Exclusion criteria
- had developed or had been diagnosed with any illness or congenital disorder that could be immediately life threatening
Trial design
343 participants in 1 patient group
All Enrolled Participants
Description:
All participants who completed Protocol 272 and were enrolled in Protocol 374
Trial contacts and locations
0
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems